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IVUS and OCT: Either or Survivor . . .
Aloke V. Finn, MD,* Y. Chandrashekhar, MD, DM,† Jagat Narula, MD, PHD‡ince its introduction over 20 years ago, in-
travascular ultrasound (IVUS) has become
the dominant imaging technology, helping
us to better understand vessel biology and
guiding interventional procedures, and providing
information on atherosclerosis progression or re-
gression in clinical trials. During this time period,
IVUS has survived many other intracoronary
techniques that have fallen by the wayside. Re-
cently, optical coherence tomography (OCT), a
far higher resolution optical imaging technique,
was approved for clinical use by the U.S. Food
and Drug Administration. Suter et al. (1), in a
State-of-the-Art review article in this issue of
iJACC, have highlighted the relative merits of
each technology currently available for intravascu-
lar imaging. However, in an era of rising medical
costs and shrinking budgets, the increasing avail-
ability and presence of such a wide array of imag-
ing technology in catheterization laboratories
raises relevant issues about what exact role such
modalities could play. It is particularly important
to discuss whether OCT will complement IVUS
or replace it, or will it be forgotten as many other
intravascular imaging modalities have?
The introduction of grey-scale IVUS in the
1980s was accompanied by validation studies
that produced highly reproducible volumetric
measurements of plaque and vessel dimensions
(2). An equally important contribution of IVUS
has been the in vivo confirmation of the con-
cept of expansive arterial remodeling (3). Posi-
tive vascular remodeling is now an accepted fea-
ture of high-risk coronary plaques (4). The
insights about the dynamic nature of coronary lu-
men dimensions have also found a following
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Sinai School of Medicine, New York, New York.among interventional cardiologists, and they have
extended the use of IVUS to obtain accurate ves-
sel dimensions for stent sizing and often to accu-
rately define lesion significance (5).
IVUS has also been instrumental in under-
standing the natural history of atherosclerosis
plaque progression. It has demonstrated the rela-
tionship between cholesterol levels and percent
atheroma volume, and has established the role of
statin drugs in plaque regression (6). The ability
of the technique to measure plaque burden has
permitted the use of IVUS-based surrogate end-
points to test the efficacy of new therapeutic
agents, which has raised the prospect of speedy
drug testing in sample sizes smaller than would
be needed for trials using hard endpoints (7).
Furthermore, development of methods to turn ra-
diofrequency data into quantitative information
with virtual histology and integrated backscatter,
have gained popularity for characterization of plaque
composition. The large multicenter PROSPECT
(Providing Regional Observations to Study Predictors
of Events in the Coronary Tree) study demonstrated
a significant association between nonculprit IVUS-de-
fined plaque characteristics and future coronary
events (8), and that necrotic cores abutting lumen
(NCAL) on virtual histology were representative of
thin-cap fibroatheroma. In addition, the PROS-
PECT trial also revealed that the fateful plaques
had evolved to be voluminous before they developed
an acute event; this is a departure from the tacitly-
held belief that plaque disruption almost always re-
sults from minimally stenotic plaques. Similar obser-
vations have been reported by the VIVA (Virtual
Histology in Vulnerable Atherosclerosis) investiga-
tors (9). Even though both studies have demon-
strated the value of NCAL, IVUS resolution of 100
to 150 m is far from adequate for the evaluation of
the plaque characteristics. Indeed, a recent histo-
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1048pathologic study in porcine coronary arteries did not
find a correlation between necrotic core size deter-
mined by real and virtual histology, questioning the
role of IVUS in detection of thin-cap fibroatheroma
(10). There is thus a need for a superior imaging
strategy that offers substantially incremental infor-
mation, such as a more precise measurement of the
thickness of fibrous cap, which is beyond the capa-
bility of conventional IVUS. This is where OCT,
with its exquisite resolution might find a place.
However, one also needs to keep in mind that while
better image quality is a good start, newer tech-
niques would need to help achieve better procedural
outcomes to find universal acceptance (7).
OCT measures backscatter of light, or optical
echoes, derived from an infrared light source di-
rected at the arterial wall, and as such, can be re-
garded as a higher resolution analog of IVUS. A
10 m resolution capability of OCT, validated
in ex vivo experiments, has allowed superior defi-
nition of the thin fibrous caps and circumferential
extent of the necrotic cores, and possibly the pres-
ence of macrophages in the fibrous cap; all of
these features are indicators of high-risk plaques
(1,4). The greater resolution of OCT also holds
promise for the evaluation of short- and long-
term vascular response to stent implantation (11–
14). There has been a strong interest in the use of
OCT for identifying stent strut coverage as a po-
tential marker of endothelialization in a follow-up
period. OCT has recently uncovered the likeli-
hood of 2 types of in-stent restenosis, with and
without neoatherosclerosis, which may carry prog-
nostic information. While interventional studies
are now using this technique more commonly,
there are no long-term data to validate the use of
this technique for the prediction of thrombotic
events. Although OCT is a powerful tool for the
assessment of vascular interior, relatively poor
depth penetration is its most important drawback,
which limits the role of OCT for evaluation of
regression in percent atheroma volume that has
required accurate estimation of vessel size and re-
modeling. However, the recent demonstration ofresponse to statin treatment has been proposed as
a superior indicator of the efficacy of intervention,
and should overcome the inadequate depth limita-
tion (15). In addition, the need for optimal clear-
ance of blood from the vessel lumen, often requir-
ing extra doses of contrast, to generate interpretable
images has also found some detractors. Further-
more, unlike operator-friendly translation of ra-
diofrequency signals into color-coded maps to de-
fine plaque types, OCT interpretation of images
relies heavily on the experience of the operator.
In the short-term it seems likely that IVUS
will continue to remain an important player in the
catheterization laboratory. It will continue to have
a role for easily evaluating lumen dimensions, op-
timizing stent expansion, and examining post-
procedure results. Its antiquity may have given it
a temporary pass from the strict requirements of
showing improved outcomes in well tested situa-
tions. Thus, even though studies did not find sig-
nificant outcome improvements with its use in
routine percutaneous coronary intervention, most
still believe that the IVUS-guidance can be help-
ful during complex interventional procedures. On
the other hand, OCT offers promise to trans-
forming the examination of the coronary vessel
wall. This technology unfortunately has suffered
from a protracted infancy. Its drawbacks notwith-
standing, potential niches of OCT, such as stent
strut coverage and accurate fibrous cap thickness
measurement, require a more rigorous validation
of long-term value. Multicenter OCT registries
have just begun and should allow formulating
some consensus statements for its incorporation
into interventional practice. With all the changes
in our decision making strategies following recent
randomized clinical trials and economics of a
health care system asking for comparative effec-
tiveness, superior resolution with OCT, while
highly desirable, has come rather late in the day.
It will be mandatory that the research in this area
focuses on obtaining crucial outcome data rather
than spend an IVUS-like course where image
quality rather than outcome quality remained theOCT-verified increase in fibrous cap thickness in focus for an inordinate amount of time (16).
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